+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures



A community-based study of Helicobacter pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures



Helicobacter 11(5): 418-424



Background: Although eradication of Helicobacter pylori infection can decrease the risk of gastric cancer, the optimal regimen for treating the general population remains unclear. We report the eradication rate (intention-to-treat and per protocol) of a community-based H. pylori therapy using the strategy of test, treat, retest, and re-treat initial treatment failures.Materials and methods: In 2004, a total of 2658 residents were recruited for C-13-urea breath testing. Participants with positive results for infection received a standard 7-day triple therapy (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and clarithromycin 500 mg twice daily), and a 10-day re-treatment (esomeprazole 40 mg once daily, amoxicillin 1 g twice daily, and levofloxacin 500 mg once daily) if the follow-up tests remained positive. Both H. pylori status and side-effects were assessed 6 weeks after treatment.Results: Among 886 valid reporters, eradication rates with initial therapy were 86.9% (95% confidence interval [CI]: 84.7-89.1%) and 88.7% (95%CI: 86.5-90.9%) by intention-to-treat and per protocol analysis, respectively. Re-treatment eradicated infection in 91.4% (95%CI: 86-96.8%) of 105 nonresponders. Adequate compliance was achieved in 798 (90.1%) of 886 subjects receiving the initial treatment and in all 105 re-treated subjects. Mild side-effects occurred in 24% of subjects. Overall intention-to-treat and per protocol eradication rates were 97.7% (95%CI: 96.7-98.7%) and 98.8% (95%CI: 98.5-99.3%), respectively, which were only affected by poor compliance (odds ratio, 3.3; 95%CI, 1.99-5.48; p < .0001).Conclusions: A comprehensive plan using drugs in which the resistance rate is low in a population combined with the strategy of test, treat, retest, and re-treat of needed can result in virtual eradication of H. pylori from a population. This provides a model for planning country- or region-wide eradication programs.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 011679241

Download citation: RISBibTeXText

PMID: 16961802

DOI: 10.1111/j.1523-5378.2006.00432.x


Related references

Helicobacter pylori and gastro-oesophageal reflux disease: association and clinical implications. To treat or not to treat with anti-H. pylori therapy?. Scandinavian Journal of Gastroenterology. Supplement: 15-18, 2002

Helicobacter pylori and Gastro-oesophageal Reflux Disease: Association and Clinical Implications: To Treat or Not to Treat with anti- H. pylori Therapy?. Scandinavian Journal of Gastroenterology 37(236): 15-18, 2002

Helicobacter pylori serology in an urban multiethnic population Test and treat or guess and treat?. Gut 52(7): 1070, 2003

Helicobacter pylori test-and-treat' strategy for dyspeptic patients. Scandinavian Journal of Gastroenterology 34(7): 644-652, 1999

Helicobacter pylori A test and treat strategy in primary care. Gastroenterology 112(4 SUPPL ): A46, 1997

The test-and-treat strategy for Helicobacter pylori in uninvestigated dyspepsia. Jaapa 16(8): 20-2, 25-8, 2004

M1128 Prep and Treat Reduces the Number Needed to Treat (Nnt); How to Succeed Eradicating Helicobacter pylori (Hp). A Strategy to Get Patient Compliance to Obtain the Best Rates. What We Do and Do Not Tell. Gastroenterology 138(5): S-338, 2010

Test-and-treat strategy for Helicobacter pylori (HP) infection in older patients. Archives of Gerontology and Geriatrics 51(3): 237-240, 2011

Costs and benefits of a test-and-treat strategy in Helicobacter pylori-infected subjects. European Journal of Gastroenterology & Hepatology 12(3): 319-325, 2000

Helicobacter pylori test and treat strategy for young dyspeptic patients: new data. Gut 50 Suppl 4: Iv47-Iv50, 2002

Helicobacter pylori test-and-treat strategy in the management of dyspepsia in primary care: an overview. Scandinavian Journal of Gastroenterology 39(4): 297-302, 2004

Value of the "Test & Treat" Strategy for Uninvestigated Dyspepsia at Low Prevalence Rates of Helicobacter pylori in the Population. Helicobacter 21(3): 186-191, 2017

Therapy of Helicobacter pylori infection: "Who to treat, how to treat?". Wiener Medizinische Wochenschrift 152(5-6): 141-147, 2002

Noninvasive Helicobacter pylori testing for the "test-and-treat" strategy: a decision analysis to assess the effect of past infection on test choice. Archives of Internal Medicine 161(17): 2129-2132, 2001

Helicobacter pylori "test-and-treat" strategy is not suitable for the management of patients with uninvestigated dyspepsia in Shanghai. Scandinavian Journal of Gastroenterology 40(9): 1028-1031, 2005